News + Resources
Keep up with the latest
Featured
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
Scribe Therapeutics Reports Preclinical Data Validating its CRISPR Genome Editing and Epigenome Modifying Technologies for Addressing Cardiometabolic Disease at American Heart Association (AHA) Scientific Sessions 2024
November 25, 2024
CRISPR 2.0, the Next Generation
June 21, 2024
Aspen Ideas: Health
CRISPR 2.0, the Next Generation
June 21, 2024
All Stories
News
Scribe Therapeutics and Sanofi collaborate on in vivo therapies for sickle cell disease
July 18, 2023
BioWorld
Read Now
Press Release
Scribe Therapeutics and Sanofi collaborate on in vivo therapies for sickle cell disease
July 18, 2023
BioWorld
Read Now
News
Sanofi expands collaboration with Scribe on CRISPR genome editing
July 18, 2023
Seeking Alpha
Read Now
Press Release
Sanofi expands collaboration with Scribe on CRISPR genome editing
July 18, 2023
Seeking Alpha
Read Now
News
East Bay's Scribe Therapeutics lands 2nd big deal with Sanofi, this one aimed initially at sickle cell disease
July 18, 2023
San Francisco Business Times
Read Now
Press Release
East Bay's Scribe Therapeutics lands 2nd big deal with Sanofi, this one aimed initially at sickle cell disease
July 18, 2023
San Francisco Business Times
Read Now
News
Sanofi taps Scribe for in vivo partnership worth more than $1.2B biobucks aimed at sickle cell and beyond
July 18, 2023
Fierce Biotech
Read Now
Press Release
Sanofi taps Scribe for in vivo partnership worth more than $1.2B biobucks aimed at sickle cell and beyond
July 18, 2023
Fierce Biotech
Read Now
News
Sanofi licenses CRISPR enzyme in bid to develop safer, simpler sickle cell cure
July 18, 2023
STAT News
Read Now
Press Release
Sanofi licenses CRISPR enzyme in bid to develop safer, simpler sickle cell cure
July 18, 2023
STAT News
Read Now
News
Scribe Therapeutics Expands Collaboration with Sanofi to Advance In Vivo Genetic Medicines for Sickle Cell and Other Genomic Diseases
July 17, 2023
Read Now
Press Release
Scribe Therapeutics Expands Collaboration with Sanofi to Advance In Vivo Genetic Medicines for Sickle Cell and Other Genomic Diseases
July 17, 2023
Read Now